ViRexx Medical Corp.

ViRexx Medical Corp.

January 19, 2006 11:43 ET

ViRexx Founders Receive BioAlberta Lifetime Achievement Award

EDMONTON, ALBERTA--(CCNMatthews - Jan. 19, 2005) - ViRexx Medical Corp. (TSX:VIR)(AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that its founders, Dr. Antoine Noujaim and Dr. Lorne Tyrrell, will receive a Lifetime Achievement Award from BioAlberta at the 6th Annual BioAlberta Gala taking place tonight in Edmonton at the Fairmount MacDonald Hotel.

"Dr. Noujaim and Dr. Tyrrell are deserving recipients of this prestigious award for their contribution to both science and the biotech industry in Alberta," said Doug Gilpin CA, Chairman of the Board of ViRexx Medical Corp. "The dedication they have demonstrated to their work and the progress they continue to make toward new medical therapies is recognized across the country and internationally. We continue to draw upon their experience and knowledge in the development and application of our immunotherapy and embolotherapy technologies."

The Lifetime Achievement Award recognizes individuals who have made extensive and tangible contributions to the Alberta and Canadian life sciences community, and honor the impact of that work on scientific achievement and research, industry development, public policy, ambassadorship, and education. Recipients are categorized as passionate advocates for science and technology, accomplished scientists and/or business leaders, and mentors to many within the industry.

About ViRexx Medical Corp.

ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B and C and solid tumors.

ViRexx's lead product candidate, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see

About BioAlberta

BioAlberta is a private, not-for-profit industry association, representing BioAlberta's growing biotechnology sector. BioAlberta currently lists over 100 members, including producers, users and supporters of biotechnology activities in Alberta. On behalf of its membership, BioAlberta promotes increased awareness and support for the growth of Alberta's biotechnology industry and biotech capabilities across all sectors.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX has not approved or disapproved of the information contained herein

Contact Information

  • ViRexx Medical Corp.
    Lorne Tyrrell
    Chief Executive Officer
    (780) 433-4411
    (780) 436-0068 (FAX)
    ViRexx Medical Corp.
    Marc Canton
    President & Chief Operating Officer
    (780) 433-4411
    (780) 436-0068 (FAX)